Empire Hails Court Victory, Aims to Advance CO2 Development
Empire Petroleum (NYSE: EP) shares triumphed Friday, as the oil and gas company with producing assets in New Mexico, North Dakota, Montana, Texas, and Louisiana, announced the New Mexico Oil Conservation Commission has issued a unanimous and favorable ruling regarding the Company’s rights to the Residual Oil Zone in the Eunice Monument South Unit Unitized Interval in Lea County, New Mexico.After four years of expenditures, Empire received the Commission’s unanimous decision at a public hearing on August 14, affirming the existence of a ROZ in the Grayburg and San Andres formations within the EMSU and confirming Empire’s exclusive rights to produce the ROZ under the 1984 Commission Order. The Commission is allowing Empire the opportunity to implement a CO2 enhanced oil recovery pilot project over the next three years.In addition to the findings noted above, the Commission unanimously ordered the following actions:• Deny five new injection well applications from Goodnight Midstream Permian, LLC (“Goodnight”);• Deny application for increased injection from Goodnight;• Suspend injection operations on four existing Goodnight injection wells; and• Deny all pending motions attached to these cases.“The Commission,” according to this morning’s news release, “further found that, while Empire did not prove immediate correlative rights impairment in the Grayburg from neighboring operators’ injection activities, the Company presented compelling evidence of possible future impairment or waste.”EP shares powered forward 29 cents, or 6.1%, to $5.01.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


